Multimodal therapy in the management of lacrimal gland adenoid cystic carcinoma
- PMID: 31176360
- PMCID: PMC6556222
- DOI: 10.1186/s12886-019-1110-5
Multimodal therapy in the management of lacrimal gland adenoid cystic carcinoma
Abstract
Background: To evaluate the prognosis of Chinese patients with lacrimal gland adenoid cystic carcinoma treated with eye-sparing surgery and adjuvant multimodal therapy.
Methods: The study included 24 consecutive patients with lacrimal gland adenoid cystic carcinoma treated at the Ninth People's Hospital of Shanghai from May 2008 to September 2017. All patients underwent eye-sparing surgical tumor resection and 20 (83.3%) of the 24 patients in the cohort received postoperative RT. Eight (41.7%) patients in the cohort received chemotherapy. Each patient's medical records were reviewed.
Results: The study included 13 male and 11 female patients. The median follow-up time after surgery was 33.5 months. Fifteen (62.5%) patients experienced local recurrence. The 1-, 3-, and 5-year recurrence rates were 27.9, 60.0, and 80.0%, respectively. Eleven (45.8%) patients developed metastasis. The 1-, 3-, and 5-year metastasis rates were 8.7, 48.5, and 66.9%, respectively. Eight (33.3%) patients died of lacrimal gland adenoid cystic carcinoma, with a median survival duration of 34.0 months. The 1-, 3-, and 5-year tumor-related mortality was 4.5, 28.1, and 58.0%, respectively. More advanced T stage (≥ T3a) was a risk factor for local recurrence (hazard ratio [HR]: 5.374, P = 0.02), distant metastasis (HR: 8.585, P < 0.01), and tumor-related survival (HR: 9.654, P < 0.01).
Conclusions: Eye-sparing tumor resection protocol followed by adjuvant therapy seems to be associated with high rates of local recurrence, metastases and death. In addition, greater attention should be paid to patients with lacrimal gland adenoid cystic carcinoma with ≥ T3a tumors.
Keywords: Eye-sparing surgery; Lacrimal gland adenoid cystic carcinoma; Local recurrence; Metastasis; Tumor-related mortality, 8th American joint committee on Cancer.
Conflict of interest statement
All authors declare that they have no competing interests.
Figures



Similar articles
-
Long-Term Outcomes of Eye-Sparing Surgery for Adenoid Cystic Carcinoma of Lacrimal Gland.Ophthalmic Plast Reconstr Surg. 2018 Jan/Feb;34(1):74-78. doi: 10.1097/IOP.0000000000000877. Ophthalmic Plast Reconstr Surg. 2018. PMID: 28221296
-
Survival outcomes of eye-sparing surgery for adenoid cystic carcinoma of lacrimal gland.Jpn J Ophthalmol. 2019 Jul;63(4):344-351. doi: 10.1007/s10384-019-00671-w. Epub 2019 May 27. Jpn J Ophthalmol. 2019. PMID: 31134459
-
American Joint Committee on Cancer classification predicts outcome of patients with lacrimal gland adenoid cystic carcinoma.Ophthalmology. 2009 Jun;116(6):1210-5. doi: 10.1016/j.ophtha.2008.12.049. Epub 2009 Apr 23. Ophthalmology. 2009. PMID: 19395039
-
Current treatment of lacrimal gland carcinoma.Curr Opin Ophthalmol. 2016 Sep;27(5):449-56. doi: 10.1097/ICU.0000000000000301. Curr Opin Ophthalmol. 2016. PMID: 27273588 Review.
-
Adenoid Cystic Carcinoma from the salivary and lacrimal glands and the breast: Different clinical outcomes to the same tumor.Crit Rev Oncol Hematol. 2022 Nov;179:103792. doi: 10.1016/j.critrevonc.2022.103792. Epub 2022 Aug 13. Crit Rev Oncol Hematol. 2022. PMID: 35973662 Review.
Cited by
-
Lacrimal Gland Adenoid Cystic Carcinoma with High Grade Transformation: A Case Report and Current Concepts in Multi Modality Management.Indian J Otolaryngol Head Neck Surg. 2022 Oct;74(Suppl 2):2599-2606. doi: 10.1007/s12070-020-02277-y. Epub 2020 Nov 25. Indian J Otolaryngol Head Neck Surg. 2022. PMID: 36452811 Free PMC article.
-
Similar therapeutic effects of 125I seed radiotherapy and γ-ray radiotherapy on lacrimal gland adenoid cystic carcinoma.Int J Ophthalmol. 2021 Apr 18;14(4):547-553. doi: 10.18240/ijo.2021.04.11. eCollection 2021. Int J Ophthalmol. 2021. PMID: 33875946 Free PMC article.
-
Multicentre clinicopathological study of adenoid cystic carcinoma: A report of 296 cases.Cancer Med. 2021 Feb;10(3):1120-1127. doi: 10.1002/cam4.3707. Epub 2021 Jan 15. Cancer Med. 2021. PMID: 33449415 Free PMC article.
-
Recurrent lacrimal gland adenoid cystic carcinoma: A case report and literature review.Heliyon. 2024 Jun 28;10(14):e33889. doi: 10.1016/j.heliyon.2024.e33889. eCollection 2024 Jul 30. Heliyon. 2024. PMID: 39108856 Free PMC article.
-
Prognostic factors for lacrimal gland adenoid cystic carcinoma: a retrospective study in Chinese patients.Int J Ophthalmol. 2024 Aug 18;17(8):1423-1430. doi: 10.18240/ijo.2024.08.06. eCollection 2024. Int J Ophthalmol. 2024. PMID: 39156780 Free PMC article.
References
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical